ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials.

December 2, 2005

DCE Board Approves Recompetition Of Two Major Contracts

October 30, 1987

NCI Programs: NCI Drug Screening To Take More Targeted Approach; BSA Okays Plan To Support New MA Contracts

April 3, 1998

Clinical Trials Approved By NCI Last Month Listed

February 22, 2002

NCI, NIH Make Half-Hearted Pitch For Cancer Act Before Seemingly Uninterested Rogers Committee

March 10, 1978

Philadelphia Firm Wins CIDAC Award

August 24, 1984